Join the 'Psoriasis' group to help and get support from people like you.

Psoriasis Blog

Related terms: Erythrodermic Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Palmo-plantar Psoriasis, Psoriasis vulgaris, Pustular Psoriasis

New Psoriasis Drug Cosentyx Approved

Posted 8 days ago by Drugs.com

WEDNESDAY, Jan. 21, 2015 – The anti-psoriasis drug Cosentyx (secukinumab) has been approved by the U.S. Food and Drug Administration. Psoriasis in an immune system disorder that causes red, scaly patches of skin. It occurs most often in people aged 15 to 35, and among those with a family history of the disease, the agency said Wednesday in a news release. Cosentyx's active ingredient is a human antibody that inhibits a protein involved in inflammation. The injected drug's safety and effectiveness were evaluated in clinical studies involving more than 2,400 people with plaque psoriasis. The drug was found to clear psoriasis plaques from skin significantly better than a placebo, the FDA said. Since the drug affects the immune system, users may be at greater risk of infection. Serious allergic reactions to Cosentyx also are possible, the FDA warned. The drug's most common side effects are ... Read more

Related support groups: Psoriasis, Plaque Psoriasis

FDA Approves Cosentyx (secukinumab) for Plaque Psoriasis

Posted 8 days ago by Drugs.com

January 21, 2015 – The U.S. Food and Drug Administration today approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis. Psoriasis is a skin condition that causes patches of skin redness and irritation. Psoriasis is an autoimmune disorder, and occurs more commonly in patients in with a family history of the disease, and most often begins in people between the ages of 15 and 35. The most common form of psoriasis is plaque psoriasis, in which patients develop thick, red skin with flaky, silver-white patches called scales. Cosentyx’s active ingredient is secukinumab. Secukinumab is an antibody that binds to a protein (interleukin (IL)-17A) which is involved in inflammation. By binding to IL-17A, secukinumab prevents it from binding to its receptor, and inhibits its ability to trigger the inflammatory response that plays a role in the development of p ... Read more

Related support groups: Psoriasis, Plaque Psoriasis

Psoriasis Costs Americans Up to $135 Billion Annually, Study Finds

Posted 8 Jan 2015 by Drugs.com

WEDNESDAY, Jan. 7, 2015 – Psoriasis is more than just a troublesome skin condition for millions of Americans – it also causes up to $135 billion a year in direct and indirect costs, a new study shows. According to data included in the study, about 3.2 percent of the U.S. population has the chronic inflammatory skin condition. "Psoriasis patients may endure skin and joint disease, as well as associated conditions such as heart disease and depression," said Dr. Amit Garg, a dermatologist at North Shore-LIJ Health System in Manhasset, N.Y. "These patients may bear significant long-term costs related to the medical condition itself, loss of work productivity, as well as to intangibles such as restriction in activities and poor self-image, for example," he added. In the new study, a team led by Dr. Elizabeth Brezinski of the University of California, Davis reviewed 22 studies to estimate ... Read more

Related support groups: Psoriasis

Psoriasis Tied to Raised Risk of Uncontrolled Blood Pressure

Posted 15 Oct 2014 by Drugs.com

WEDNESDAY, Oct. 15, 2014 – People with more severe cases of psoriasis may be at increased risk of uncontrolled high blood pressure, a large study finds. Researchers looking at over 13,000 adults in the United Kingdom found that those with severe psoriasis were 48 percent more likely to have poorly controlled blood pressure, versus people without the skin condition. The findings, reported online Oct. 15 in the journal JAMA Dermatology, confirm an association between psoriasis and cardiovascular health. But the precise reasons are not clear, and a cause-and-effect link was not proven. "We still don't fully understand why we see a higher prevalence of cardiovascular risk factors in people with psoriasis," said study leader Dr. Junko Takeshita, a clinical instructor of dermatology at the University of Pennsylvania in Philadelphia. But, Takeshita said, chronic inflammation could be a common ... Read more

Related support groups: High Blood Pressure, Hypertension, Psoriasis

FDA Approves Otezla (apremilast) for Moderate to Severe Plaque Psoriasis

Posted 23 Sep 2014 by Drugs.com

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate. Otezla is the first and only PDE4 inhibitor approved for the treatment of plaque psoriasis. Psoriasis, a chronic inflammatory disease of the skin resulting from an uncontrolled immune response, affects more than 125 million people worldwide. "Otezla offers an important new treatment option for patients whose symptoms are not adequately improving with their current treatments. In clinical trials, Otezla reduced redness, thickness, and scaliness of plaques in patients with moderate or severe plaque psoriasis," said Dr. M. Shane Chapman, ... Read more

Related support groups: Psoriasis, Plaque Psoriasis, Otezla, Apremilast

Psoriasis Treatment Choices Improving, FDA Says

Posted 5 Sep 2014 by Drugs.com

FRIDAY, Sept. 5, 2014 – A growing knowledge of the skin disease called psoriasis is leading to greater treatment choices, including personalized therapies, the U.S. Food and Drug Administration reports. Psoriasis is an immune system disorder that causes overproduction of skin cells, resulting in scaling, pain, swelling, redness and heat. The condition affects about 7.5 million Americans. "As we better understand the disease, researchers know more about what specific factors to target in order to develop effective treatments," FDA dermatologist Dr. Melinda McCord said in an agency news release. There is no cure for psoriasis, so the main goals of treatments are to stop skin cell overproduction and reduce inflammation. Current therapies include medicines applied to the skin (topical), light treatment (phototherapy), or drugs taken by mouth or given by injection. Doctors used to take a ... Read more

Related support groups: Psoriasis

FDA Approves Rasuvo (methotrexate) Injection

Posted 14 Jul 2014 by Drugs.com

Chicago, IL, July 14, 2014 – Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration (FDA) has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis. Rasuvo will be available in 10 dosage strengths, ranging from 7.5 mg to 30 mg in 2.5 mg increments and will be launched in the U.S. The company concurrently announced that the U.S. District Court for the District of Delaware has denied a motion for a preliminary injunction filed by Antares Pharma, Inc. “We’re delighted to have secured approval for our lead product, Rasuvo, and look forward to introducing this much-needed therapy to the ma ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Psoriasis, Juvenile Idiopathic Arthritis

New Psoriasis Drug Shows Promise in Trials

Posted 10 Jul 2014 by Drugs.com

WEDNESDAY, July 9, 2014 – A new psoriasis drug delivered dramatic results in two clinical trials, perhaps heralding an effective new treatment for patients with the chronic skin disease. The drug, secukinumab, was stacked up against an inactive placebo and one of the best psoriasis medications on the market. "Over a quarter of patients have not a dot of psoriasis left," said study co-author Dr. Mark Lebwohl, chairman of dermatology at the Icahn School of Medicine at Mount Sinai in New York City. "Over half the patients have a 90 percent improvement in their psoriasis, and that means there's hardly any psoriasis left. This kind of data is better than anything we've seen in the past," he added. The study results were published online July 9 in the New England Journal of Medicine. Psoriasis causes overproduction of skin cells, which results in thick red marks and flaky white lesions that ... Read more

Related support groups: Psoriasis

High Blood Pressure May Up Psoriasis Risk for Women

Posted 3 Jul 2014 by Drugs.com

WEDNESDAY, July 2, 2014 – Women with high blood pressure may have an increased risk of developing the skin disease psoriasis, new research suggests. Taking blood pressure medications called beta-blockers also raises the risk for psoriasis, according to the study that followed nearly 78,000 women for more than a decade. Psoriasis, which affects about 3 percent of the U.S. population, is a chronic immune system disorder that causes red, raised patches on the skin. Previous research has linked psoriasis with diabetes, heart disease and depression. "We basically found those who have high blood pressure of a certain duration – more than six years in this study – have an increased risk of developing psoriasis," said study researcher Dr. Abrar Qureshi, professor of dermatology at the Warren Alpert Medical School at Brown University in Providence, R.I. After six years, their risk for ... Read more

Related support groups: High Blood Pressure, Hypertension, Psoriasis

Steroids Often Prescribed for Psoriasis, Countering Guidelines

Posted 28 Feb 2014 by Drugs.com

FRIDAY, Feb. 28, 2014 – Although corticosteroid pills are not recommended for the management of psoriasis, new research reveals these drugs are commonly prescribed by dermatologists treating this chronic skin condition. Corticosteroids, including prednisone, dexamethasone and methylprednisolone, were the second most commonly prescribed systemic medications (not preparations applied to the skin) for psoriasis, according to a study from Wake Forest Baptist Medical Center. "Expert guidelines discourage their use for psoriasis due to concerns about causing flares of generalized pustular psoriasis, but there are no randomized controlled trials of systemic corticosteroids in psoriasis to look at these issues," study co-author Scott Davis, assistant director of the Center for Dermatology Research at Wake Forest Baptist Medical Center, said in a Wake Forest news release. In conducting the ... Read more

Related support groups: Prednisone, Psoriasis, Methylprednisolone, Medrol, Dexamethasone, Decadron, Solu-Medrol, Depo-Medrol, Medrol Dosepak, MethylPREDNISolone Dose Pack, Deltasone, Sterapred, Decadron Tablets, Sterapred DS, A-methapred, Dexpak Taperpak, Rayos, Adrenocot LA, Liquid Pred, Adrenocot

Study Sees Link Between Psoriasis, Kidney Problems

Posted 16 Oct 2013 by Drugs.com

TUESDAY, Oct. 15 – People with moderate to severe psoriasis are at increased risk for chronic kidney disease and need to be closely monitored for kidney problems, a large new study suggests. Researchers in Philadelphia analyzed data from nearly 144,000 people, aged 19 to 90, with psoriasis, and a comparison (control) group of nearly 690,000 adults without the condition. During seven years of follow-up, people with psoriasis were more likely to develop chronic kidney disease than those in the control group. Those with severe psoriasis had a nearly two-fold higher risk of developing kidney disease and a more than fourfold higher risk of developing kidney failure requiring dialysis, according to a journal news release Further investigation that focused on the amount of skin area affected by psoriasis showed that people with moderate to severe psoriasis were at greater risk of developing ... Read more

Related support groups: Psoriasis, Chronic Kidney Disease

Otrexup (Methotrexate) Injection Approved By FDA

Posted 15 Oct 2013 by Drugs.com

EWING, N.J., October 14, 2013 — Antares Pharma, Inc. today announced the approval of Otrexup (methotrexate) injection by the U.S. Food and Drug Administration (FDA). Otrexup is the first FDA approved subcutaneous (SC) methotrexate (MTX) for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. Otrexup is indicated for adults with severe active rheumatoid arthritis (RA) who have had an insufficient therapeutic response to or are intolerant of an adequate trial of first line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs), or children with active polyarticular juvenile idiopathic arthritis (pJIA). The FDA also approved adult use of Otrexup for symptomatic control of severe recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy. In 2012, approximately six million prescriptions were w ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Psoriasis, Juvenile Rheumatoid Arthritis, Juvenile Idiopathic Arthritis

Skin Care Tips for Psoriasis Patients

Posted 23 Aug 2013 by Drugs.com

FRIDAY, Aug. 23 – Sun protection is among the skin care habits that can help people with the chronic skin condition psoriasis reduce some of the discomfort they may experience, such as skin itching, cracking and bleeding, an expert says. "It's extremely important for people with psoriasis to protect their skin from excessive sun," Dr. Stephen Stone, a professor of dermatology and director of clinical research at Southern Illinois University School of Medicine, said in an American Academy of Dermatology news release. "Being exposed to the sun for too long can worsen existing psoriasis and cause new psoriasis to form." Psoriasis causes red, scaly patches on the skin of the scalp, elbows or other parts of the body. The condition is believed to be caused by an interaction of genes, the immune system and the environment. Along with emphasizing sun protection, Stone offered other tips to ... Read more

Related support groups: Psoriasis

Many Psoriasis Patients Going Without Treatment, Study Finds

Posted 14 Aug 2013 by Drugs.com

WEDNESDAY, Aug. 14 – The autoimmune skin disorder known as psoriasis affects millions of Americans, but a new study suggests it remains woefully undertreated. In 2011, between 30 percent and nearly 50 percent of patients said they had no treatment for their psoriasis, depending on the severity of their disease. One expert unconnected to the study said he wasn't surprised by the findings. "Dermatologists, especially those that specialize in caring for patients with psoriasis, are well aware of the fact that many patients are untreated or undertreated," said Dr. Gary Goldenberg, an assistant professor of dermatology at the Icahn School of Medicine at Mount Sinai, in New York City. "This is especially concerning for those patients with moderate to severe disease and those with psoriatic arthritis, which affects approximately 30 percent of patients with psoriasis." Psoriasis is an immune ... Read more

Related support groups: Psoriasis

Psoriasis, Other Medical Conditions May Be Linked, Study Says

Posted 7 Aug 2013 by Drugs.com

WEDNESDAY, Aug. 7 – People with the skin disease psoriasis may be at increased risk for other major health problems, according to a new study. The link between psoriasis, which is characterized by irritated, red patches of skin, and other medical conditions has been unclear. In this study, published online Aug. 7 in the journal JAMA Dermatology, researchers analyzed data from more than 9,000 British psoriasis patients, aged 25 to 64. They compared them with more than 90,000 age-matched people without psoriasis. Among the psoriasis patients, the disease was mild in nearly 52 percent, moderate in nearly 36 percent and severe in about 12 percent. The analysis revealed that people with psoriasis had higher rates of chronic lung disease, diabetes, mild liver disease, heart attack, peptic ulcer, peripheral vascular disease, kidney disease and rheumatologic disease. The risk of having these ... Read more

Related support groups: Psoriasis

Page 1 2 3 4 Next

Ask a Question

Further Information

Related Condition Support Groups

Plaque Psoriasis, Psoriatic Arthropathy, Dermatological Disorders

Related Drug Support Groups

prednisone, methotrexate, Humira, methylprednisolone, Remicade, triamcinolone, dexamethasone, clobetasol, Therapeutic, view more... fluocinonide, Kenalog, Clobex, desonide, cyclosporine, Stelara, hydroxyurea, desoximetasone, Elocon, Soriatane, Topicort, Dovonex, Lidex, infliximab, Tazorac, Cordran, acitretin, Halog, Olux, coal tar, Cloderm, Kenalog-40, Kenalog-10, Acthar, Acth, Cordran Tape, Neoral, etanercept, Locoid, Cortizone-10, feverfew, halobetasol, Deltasone, Temovate, Eczema Cream, Olux-E, Vanos, calcipotriene, Acthar Gel, HP, Cortaid, adalimumab, ustekinumab, resorcinol, tazarotene, Dermovate, halcinonide, Anucort-HC, methoxsalen, Analpram-HC, betamethasone / calcipotriene, Locoid Lipocream, anthralin, Ultravate, Vectical, Linotar Gel 2, Proctofoam HC, Cyclocort, Aristocort A, Linotar, Verdeso, Gengraf, Taclonex, alclometasone, Sterapred, Soriatane CK, Sterapred DS, Cortaid Maximum Strength, Methotrexate LPF Sodium, Liquid Pred, Aristocort for Injection, Triderm, Hemorrhoidal HC, DHS Tar Shampoo, Aquanil HC, Cortane, MG 217 Psoriasis, Neutrogena T / Derm, Doak Tar Oil, Doak Oil Forte, Corticaine, Zone-A, Pandel, Desonate, Dermarest Dricort, Oxsoralen-Ultra, Coal Tar Strong, Hycort, Aristocort R, Linotar Gel 3, Proctozone HC, Psoriasin, Halog-E, Amevive, Hytone, hydrocortisone / pramoxine, diflorasone, Trianex, Dritho-Scalp, Psoriatec, Doak Tar, DesOwen, Dermatop, Fototar, Anti-Dandruff, Topicort LP, corticotropin, Pramosone, Aristospan, Aclovate, Zithranol, Taclonex Scalp, Trexall, Nutracort, X-Seb T Plus, Anurx-HC, Dermacort, Anutone-HC, Calcitrene, Cetacort, Cort-Dome High Potency, Ala-Scalp HP, Aloe Cort, Caldecort, Corticreme, Delcort, Rasuvo, Sorilux, Otrexup, Acticort 100, HC Pram, Cortaid with Aloe, Lacticare-HC, Proctocort, Procto-Kit 2.5%, Proctosol-HC, Anuprep-HC, Procto-Kit 1%, Texacort, Aeroseb-HC, Carb-O-Lac5, Keratol HC, Anthrascalp, Rectasol-HC, Penecort, Cotacort, Westcort, Ala-Cort, Hydrocort cream, Dermol HC, Anumed-HC, Hemril-HC Uniserts, Anthraforte, Nogenic HC, U-Cort, Proctosert HC, Cortaid Intensive Therapy, Encort, NuZon, Fluocinonide-E, Proctozone-H, Dermtex HC, Anuzone HC, Cortizone-10 Plus, Hemril-30, Gynecort Maximum Strength, Procto-Pak 1%, OraMagic Rx, Temovate E, Ultralytic, Ultravate PAC, Dermagesic, Olux / Olux-E Kit, Scytera, Itch-X Lotion, Z-Xtra, Resinol, Neutrogena T-Scalp, Cortizone for Kids, Sarnol-HC, Zithranol-RR, Scalp-Aid, Cormax Scalp, Cort-Dome, Rederm, Recort Plus, Dermolate, Gly-Cort, Hi-Cor, Ala-Scalp, Genasone / Aloe, Instacort 10, Nupercainal HC 1%, Scalacort, Dermarest Plus Anti-Itch, Cortizone-5, Hydrocortisone 1% In Absorbase, Proctocream-HC, Scalp-Cort, Beta HC, Ivocort, Analpram E, Halonate, Rectocort HC, Triam-A, Triamonide 40, Kenaject-40, Cort-K, Tramacort-D, Tristoject, Triam-Forte, Orasone, Meticorten, Prednicen-M, Prednicot, TAC 3, Triamcot, Trilog, A-Fil, Micanol, Temovate Emollient, Cormax, Embeline E, Drithocreme, Anthra-Derm, U-Tri-Lone, Trilone, Clinacort, Clinalog, Ken-Jec 40, Folex PFS, Tarsum, benzocaine / pyrilamine / zinc oxide, prednicarbate, ammonium lactate / halobetasol, Embeline, MG217 Medicated Tar, flurandrenolide, efalizumab, amcinonide, alefacept, ammonium lactate / urea, clocortolone, coal tar / salicylic acid, Medotar, Ionil T, ProctoCare-HC, Epifoam, Instacort, Scalpicin, 8-MOP, Cordran SP, Lidex-E, LoKara, Tridesilon, Apexicon, Maxiflor, Raptiva, Clobevate, Delonide, Doctar, Polytar, Cutar, Elta Tar, Reme-T, Psorigel, Tegrin Medicated Soap, Betatar Gel, Balnetar, Theraplex T, Oxipor VHC, Pentrax Gold, Exorex, Polytar Mild, Pinetarsol Tar, Apha Keri Tar Gel, R A Acne, Dovobet, Utralytic, Orion Coal Tar, Apha Keri Tar, Clinitar, Psoriderm, Alphosyl, Alphosyl 2 in 1, Carbo-Dome, Estar, Pentrax, Triacet, Fluex, Aricin, Delta-Tritex, Flutex, Dermacin, Licon, Psorcon, Florone, Florone E, Psorcon E, ApexiCon E, Rx Triamcinolone, Cinalog, Zeprime Tar Emulsion, G-TAR, Ionil T Plus, Neutrogena T / Gel, Tegrin Medicated, Zetar, HC Pramoxine, Enzone, Cinolar, Zone-A Forte, Novacort, Hydropram, Ultralytic 2